Clinical trial
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)
NCT04213794 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 8, 2019
- Completion date
- October 3, 2024
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
malignant abdominal neoplasm, malignant pelvic neoplasm, recurrent colon carcinoma, recurrent desmoplastic small round cell tumor, recurrent fallopian tube carcinoma, recurrent gastric carcinoma, recurrent liposarcoma, recurrent malignant mesothelioma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, recurrent rectal carcinoma, recurrent rhabdomyosarcoma, recurrent sarcoma, refractory colon carcinoma, refractory desmoplastic small round cell tumor, refractory fallopian tube carcinoma, refractory gastric carcinoma, refractory liposarcoma, refractory malignant mesothelioma, refractory ovarian carcinoma, refractory primary peritoneal carcinoma, refractory rectal carcinoma, refractory rhabdomyosarcoma, refractory sarcoma, resectable liposarcoma, resectable malignant mesothelioma, resectable sarcoma